3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow CS1001 placebo: new trials by email Literature Review of CS1001 placebo trials Research Report on CS1001 placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma CS1001 monoclonal antibody, CS1001 placebo, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Completed | CStone Pharmaceuticals | 479 | 2019-03-28 | 2023-11-29 |
| A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer CS1001 monoclonal antibody, CS1001 placebo - Non Small Cell Lung Cancer | Phase 3 | Completed | CStone Pharmaceuticals | 479 | 2018-12-13 | 2026-08-18 |
| A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer CS1001 monoclonal antibody, CS1001 placebo - Non-Small Cell Lung Cancer Stage III | Phase 3 | Completed | CStone Pharmaceuticals | 381 | 2018-10-26 | 2023-06-15 |
Carcinoma, Non-Small-Cell Lung (2)
China (3)
Qing Zhou (1)
PMID 35038429, PMID 35038432, PMID 37322367, PMID 39992668, PMID 40523368